Ultragenyx Pharmaceutical Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Ultragenyx Pharmaceutical Inc. (RARE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are RARE insiders buying or selling?
In the last 12 months, Ultragenyx Pharmaceutical Inc. insiders reported 0 open-market purchases ($0) and 23 sales ($3.6M) — net selling of $3.6M. Since May 2018, Trabud has recorded 193 Form 4 filings for RARE: 1 buys ($218.2K) and 192 sells ($87.1M).
Source: SEC EDGAR Form 4
What stands out
- No Ultragenyx Pharmaceutical Inc. insider made an open-market purchase in the last 12 months; the 23 reported open-market sales totaled $3.6M.
Key Statistics (May 2018 – Sep 15, 2026)
Total Form 4 filings
193
SEC EDGAR
Insider filers
17
Insider buys (1)
$218.2K
Insider sells (192)
$87.1M
Insider sentiment
Net sellingNet insider flow of $86.9M in net selling since May 2018, and $3.6M in net selling over the last 12 months.
Recent RARE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 1.3K | $13.57 | $17.4K | SEC ↗ |
| Sep 8, 2026 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 161 | $13.99 | $2.3K | SEC ↗ |
| Aug 4, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 1.9K | $24.92 | $47.3K | SEC ↗ |
| Aug 4, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $24.92 | $117.0K | SEC ↗ |
| Jul 6, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $33.13 | $155.6K | SEC ↗ |
| Jun 15, 2026 | Corazon (Corsee) D. Sanders | Director | Sale | 2.0K | $25.05 | $50.1K | SEC ↗ |
| Jun 15, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 1.9K | $24.62 | $46.8K | SEC ↗ |
| Jun 1, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $23.77 | $110.6K | SEC ↗ |
| May 18, 2026 | Shehnaaz Suliman | Director | Sale | 5.7K | $25.12 | $144.2K | SEC ↗ |
| May 6, 2026 | Eric Crombez | EVP and Chief Medical Officer | Sale | 344 | $24.96 | $8.6K | SEC ↗ |
| May 4, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $24.90 | $116.6K | SEC ↗ |
| Apr 2, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $20.97 | $98.2K | SEC ↗ |
| Mar 10, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 9.5K | $21.87 | $208.3K | SEC ↗ |
| Mar 4, 2026 | John Richard Pinion | EVP, Chief Quality Operations Officer | Sale | 10.0K | $22.80 | $228.7K | SEC ↗ |
| Mar 4, 2026 | Erik Harris | EVP & Chief Commercial Officer | Sale | 10.5K | $22.80 | $240.3K | SEC ↗ |
| Mar 4, 2026 | Emil D Kakkis | President & CEO | Sale | 54.4K | $22.80 | $1.2M | SEC ↗ |
| Mar 3, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 8.1K | $22.80 | $185.5K | SEC ↗ |
| Mar 3, 2026 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 1.6K | $22.80 | $37.2K | SEC ↗ |
| Mar 3, 2026 | Howard Horn | Chief Financial Officer | Sale | 10.0K | $22.65 | $227.5K | SEC ↗ |
| Mar 3, 2026 | Eric Crombez | EVP and Chief Medical Officer | Sale | 7.0K | $22.80 | $160.3K | SEC ↗ |
| Feb 3, 2026 | Howard Horn | Chief Financial Officer | Sale | 3.1K | $23.56 | $72.1K | SEC ↗ |
| Dec 30, 2025 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 85 | $34.38 | $2.9K | SEC ↗ |
| Dec 11, 2025 | Howard Horn | Chief Financial Officer | Sale | 3.1K | $36.38 | $112.1K | SEC ↗ |
| Oct 14, 2025 | Howard Horn | Chief Financial Officer | Sale | 7.9K | $31.51 | $250.3K | SEC ↗ |
| Sep 19, 2025 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 64 | $29.17 | $1.9K | SEC ↗ |
Showing the 25 most recent of 193 Form 4 filings for Ultragenyx Pharmaceutical Inc..
Most active RARE insiders
- Karah Herdman Parschauer33 filings
- Theodore Alan Huizenga30 filings
- Emil D Kakkis18 filings
- Erik Harris16 filings
- John Richard Pinion12 filings
Ask anything about RARE insider activity
Use Trabud's AI agent to query Ultragenyx Pharmaceutical Inc.'s Form 4 history in plain English — "Show me RARE CEO purchases this year" or compare it against any other ticker.
Open the AI agentRARE insider trading FAQ
Are Ultragenyx Pharmaceutical Inc. insiders buying or selling?
In the last 12 months, Ultragenyx Pharmaceutical Inc. insiders reported 0 open-market purchases ($0) and 23 sales ($3.6M) — net selling of $3.6M. Since May 2018, Trabud has recorded 193 Form 4 filings for RARE: 1 buys ($218.2K) and 192 sells ($87.1M). Over the full record that is net selling of $86.9M.
How many insiders trade RARE stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Ultragenyx Pharmaceutical Inc.. The most recent filing was accepted on Sep 15, 2026.
Where does Trabud get RARE insider trading data?
All RARE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.